Kymera Therapeutics (KYMR) Misses Q2 EPS by 12c

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.95), $0.12 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $11.48 million versus the consensus estimate of $20 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• CrowdStrike (CRWD) PT Raised to $235 at TD Cowen
• Globalstar confirms launch of 8 HIBLEO-4 replacement satellites